National and Kapodistrian University of Athens
Επίδραση της συστηματικής χορήγησης bevacizumab στην καρδιοαγγειακή πρόγνωση ογκολογικών ασθενών
Abstract
dc:descriptionBevacizumab is an antibody against VEGF, widely used in the treatment of cancer. Aim of the present study is the evaluation of its impact in the cardiovascular prognosis of cancer patients.A sample of 147 patients suffering from metastatic breast or colorectal cancer were staged and planned to receive first line therapy of conventional chemo, with the addition of bevacizumab or not, according to the discretion of the oncologist. All patients were evaluated before the initiation of the therapy, at 6 and 18 months after the end of it. The 18-month estimate for freedom from cardiovascular event was 88.4±4.1% for bevacizumab and 98.6±1.4% for the controls (p=0.05). All cardiovascular events were myocardial infarctions and were significantly higher in the bevacizumab group compared to the control group (9.21% versus 1.40%, p=0.03). Multivariate analysis showed that the use of bevacizumab and the presence of LBBB and the use of bevacizumab were the only independent predictors of cardiovascular events (p<0.001).Regarding echocardiographic evaluation, the Sa wave, the index evaluating the systolic function of myocardium, was significantly lower at 6 months (10.93±4.64 versus 9.90±3.59 cm/s, p=0.0007), and remained significantly lower at 18 months (10.93±4.64 versus 9.03±9.56 cm/s, p=0.003). Regarding measurements evaluating the diastolic function, E/E ratio significantly increased both at 6 months (5.83±2.53 versus 7.86±3.45, p=0.0005), and at 18 months follow up (5.83±2.53 versus 7.84±3.45, p=0.004).
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Michelongona, Archontoula
- Μιχελόγγονα, Αρχοντούλα
Subjects
dc:subject × 16- Μπεβασιζουμάμπη
- Αναστολέας αγγειογένεσης
- Αγγειογένεση
- Καρδιοαγγειακή πρόγνωση
- Αντίσωμα
- Bevacizumab
- Vascular endothelial growth factor
- Angiogenesis
- Cardiovascular prognosis
- Antibody
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Επιστήμες Υγείας
- Medical and Health Sciences
- Clinical Medicine
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42481